{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:11:32Z","timestamp":1794492692169,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR300967"],"award-info":[{"award-number":["NIHR300967"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.lanepe.2022.100416","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:59:50Z","timestamp":1653508790000},"page":"100416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Management of gout following 2016\/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom"],"prefix":"10.1016","volume":"18","author":[{"given":"Mark D","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Douiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C","family":"Gulliford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P","family":"Cope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lanepe.2022.100416_bib0001","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.lanepe.2022.100416_bib0002","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","article-title":"Gout and hyperuricaemia in the USA: prevalence and trends","volume":"58","author":"Singh","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.lanepe.2022.100416_bib0003","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","article-title":"The British society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.lanepe.2022.100416_bib0004","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kex521","article-title":"Management of gout by UK rheumatologists: a British Society for Rheumatology national audit","volume":"57","author":"Roddy","year":"2018","journal-title":"Rheumatology"},{"issue":"10156","key":"10.1016\/j.lanepe.2022.100416_bib0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lanepe.2022.100416_bib0006","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and Decadal Trends: the National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.lanepe.2022.100416_bib0007","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100416_bib0008","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.lanepe.2022.100416_bib0009","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3899\/jrheum.150310","article-title":"An Observational study of gout prevalence and quality of care in a national australian general practice population","volume":"42","author":"Robinson","year":"2015","journal-title":"J Rheumatol"},{"issue":"1485","key":"10.1016\/j.lanepe.2022.100416_bib0010","first-page":"8","article-title":"Gout in Aotearoa New Zealand: the equity crisis continues in plain sight","volume":"131","author":"Dalbeth","year":"2018","journal-title":"N Z Med J"},{"key":"10.1016\/j.lanepe.2022.100416_bib0011","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","article-title":"Epidemiology and management of gout in Taiwan: a nationwide population study","volume":"17","author":"Kuo","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100416_bib0012","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13075-016-1211-y","article-title":"Factors associated with initiation and persistence of urate-lowering therapy","volume":"19","author":"Dehlin","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100416_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lanepe.2022.100416_bib0014","series-title":"CPRD","year":"2021"},{"key":"10.1016\/j.lanepe.2022.100416_bib0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1536867X1501500208","article-title":"Conducting interrupted time-series analysis for single- and multiple-group comparisons","volume":"15","author":"Linden","year":"2015","journal-title":"Stata J"},{"issue":"5","key":"10.1016\/j.lanepe.2022.100416_bib0016","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.dsx.2020.06.042","article-title":"Impact of COVID-19 on routine care for chronic diseases: a global survey of views from healthcare professionals","volume":"14","author":"Chudasama","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"10.1016\/j.lanepe.2022.100416_bib0017","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100416_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003627","article-title":"Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study","volume":"4","author":"Goldfien","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100416_bib0019","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-018-1585-0","article-title":"Accuracy of the HumaSens(plus) point-of-care uric acid meter using capillary blood obtained by fingertip puncture","volume":"20","author":"Fabre","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.lanepe.2022.100416_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1586\/14737159.2016.1134326","article-title":"An analytical comparison between point-of-care uric acid testing meters","volume":"16","author":"Paraskos","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"issue":"10","key":"10.1016\/j.lanepe.2022.100416_bib0021","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.lanepe.2022.100416_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.582680","article-title":"Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective","volume":"11","author":"Yu","year":"2020","journal-title":"Front Pharmacol"},{"issue":"14","key":"10.1016\/j.lanepe.2022.100416_bib0023","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100416_bib0024","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3899\/jrheum.200347","article-title":"Gout, Crystal Arthritis N. variability in urate-lowering therapy prescribing: a gout, hyperuricemia and crystal-associated disease network (G-CAN) physician survey","volume":"48","author":"Stamp","year":"2021","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100416_bib0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcp.12799","article-title":"Predicting allopurinol response in patients with gout","volume":"81","author":"Wright","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.lanepe.2022.100416_bib0026","series-title":"Healthcare across the UK: A Comparison of the NHS in England, Scotland, Wales and Northern Ireland","author":"National Audit Office","year":"2012"},{"key":"10.1016\/j.lanepe.2022.100416_bib0027","series-title":"Quality in Healthcare in England, Wales, Scotland, Northern Ireland: An Intra-UK Chartbook","author":"Sutherland","year":"2009"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100416_bib0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.lanepe.2022.100416_bib0029","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2125.1997.00647.x","article-title":"Omeprazole, other antiulcer drugs and newly diagnosed gout","volume":"44","author":"Meier","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.lanepe.2022.100416_bib0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.lanepe.2022.100416_bib0031","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.lanepe.2022.100416_bib0032","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776222001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:48:40Z","timestamp":1763009320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776222001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"alternative-id":["S2666776222001107"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100416","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of gout following 2016\/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100416"}}